P53 mutations in advanced cancers: Clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy

Oncotarget

Volumn 4, Issue 5, 2013, Pages 705-714

  Said, Rabih ^a   Hong, David S ^a   Warneke, Carla L ^a   Lee, J Jack ^a   Wheler, Jennifer J ^a   Janku, Filip ^a   Naing, Aung ^a   Falchook, Gerald S ^a   Fu, Siqing ^a   Piha Paul, Sarina ^a   Tsimberidou, Apostolia M ^a   Kurzrock, Razelle ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bevacizumab; Li Fraumeni syndrome; P53 mutations; PTEN loss

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE LOSS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; PTEN GENE; RACE DIFFERENCE; RETROSPECTIVE STUDY; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 84880321253     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.974     Document Type: Article

References (46)

1. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. 1991. p53 mutations in human cancers. Science 253:49-53.
2. Baker, S.J., Fearon, E.R., Nigro, J.M., Hamilton, S.R., Preisinger, A.C., Jessup, J.M., vanTuinen, P., Ledbetter, D.H., Barker, D.F., Nakamura, Y., et al. 1989. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217-221.
3. Edlund, K., Larsson, O., Ameur, A., Bunikis, I., Gyllensten, U., Leroy, B., Sundstrom, M., Micke, P., Botling, J., and Soussi, T. 2012. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A 109:9551-9556.
4. Pavletich, N.P., Chambers, K.A., and Pabo, C.O. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes & development 7:2556-2564.
5. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R.W. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer research 51:6304-6311.
6. Ravi, R., Mookerjee, B., Bhujwalla, Z.M., Sutter, C.H., Artemov, D., Zeng, Q., Dillehay, L.E., Madan, A., Semenza, G.L., and Bedi, A. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1alpha. Genes & development 14:34-44.
7. Moll, U.M., and Petrenko, O. 2003. The MDM2-p53 interaction. Mol Cancer Res 1:1001-1008.
8. Kojima, K., Konopleva, M., McQueen, T., O'Brien, S., Plunkett, W., and Andreeff, M. 2006. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcriptiondependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108:993-1000.
9. Azmi, A.S., Aboukameel, A., Banerjee, S., Wang, Z., Mohammad, M., Wu, J., Wang, S., Yang, D., Philip, P.A., Sarkar, F.H., et al. 2010. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 46:1122-1131.
10. Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R.S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. 2008. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 105:3933-3938.
11. Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. 2009. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53- deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 8:2992-3000.
12. Caulin, C., Nguyen, T., Lang, G.A., Goepfert, T.M., Brinkley, B.R., Cai, W.W., Lozano, G., and Roop, D.R. 2007. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 117:1893-1901.
13. Liu, G., McDonnell, T.J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-Naggar, A.K., and Lozano, G. 2000. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A 97:4174- 4179.
14. Birch, J.M., Hartley, A.L., Tricker, K.J., Prosser, J., Condie, A., Kelsey, A.M., Harris, M., Jones, P.H., Binchy, A., Crowther, D., et al. 1994. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li- Fraumeni families. Cancer Res 54:1298-1304.
15. Chompret, A., Abel, A., Stoppa-Lyonnet, D., Brugieres, L., Pages, S., Feunteun, J., and Bonaiti-Pellie, C. 2001. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38:43-47.
16. Servomaa, K., Kiuru, A., Kosma, V.M., Hirvikoski, P., and Rytomaa, T. 2000. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Molecular pathology : MP 53:24-30.
17. Lai, H., Lin, L., Nadji, M., Lai, S., Trapido, E., and Meng, L. 2002. Mutations in the p53 tumor suppressor gene and early onset breast cancer. Cancer biology & therapy 1:31- 36.
18. Shiao, Y.H., Chen, V.W., Scheer, W.D., Wu, X.C., and Correa, P. 1995. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer research 55:1485-1490.
19. Li, L.Y., Tang, J.T., Jia, L.Q., and Li, P.W. 2005. Mutations of p53 gene exons 4-8 in human esophageal cancer. World journal of gastroenterology : WJG 11:2998-3001.
20. Muller, P.A., Vousden, K.H., and Norman, J.C. 2011. p53 and its mutants in tumor cell migration and invasion. The Journal of cell biology 192:209-218.
21. Tullo A., D'Erchia, A.M., Honda, K., Mitry, R.R., Kelly, M.D., Habib, N.A., Saccone, C., and Sbisa, E. 1999. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. Clinical cancer research : an official journal of the American Association for Cancer Research 5:3523-3528.
22. Morton, J.P., Timpson, P., Karim, S.A., Ridgway, R.A., Athineos, D., Doyle, B., Jamieson, N.B., Oien, K.A., Lowy, A.M., Brunton, V.G., et al. 2010. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America 107:246-251.
23. Eastham, J.A., Stapleton, A.M., Gousse, A.E., Timme, T.L., Yang, G., Slawin, K.M., Wheeler, T.M., Scardino, P.T., and Thompson, T.C. 1995. Association of p53 mutations with metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 1:1111-1118.
24. Li, F.P., Fraumeni, J.F., Jr., Mulvihill, J.J., Blattner, W.A., Dreyfus, M.G., Tucker, M.A., and Miller, R.W. 1988. A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362.
25. Kast, K., Krause, M., Schuler, M., Friedrich, K., Thamm, B., Bier, A., Distler, W., and Kruger, S. 2012. Late onset Li- Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. BMC Cancer 12:217.
26. Gonzalez, K.D., Noltner, K.A., Buzin, C.H., Gu, D., Wen-Fong, C.Y., Nguyen, V.Q., Han, J.H., Lowstuter, K., Longmate, J., Sommer, S.S., et al. 2009. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27:1250-1256.
27. Agapova, L.S., Ilyinskaya, G.V., Turovets, N.A., Ivanov, A.V., Chumakov, P.M., and Kopnin, B.P. 1996. Chromosome changes caused by alterations of p53 expression. Mutation research 354:129-138.
28. Salmena, L., Carracedo, A., and Pandolfi, P.P. 2008. Tenets of PTEN tumor suppression. Cell 133:403-414.
29. Feng, Z., Zhang, H., Levine, A.J., and Jin, S. 2005. The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America 102:8204-8209.
30. Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., and Mak, T.W. 2001. Regulation of PTEN transcription by p53. Molecular cell 8:317-325.
31. Riedel, F., Gotte, K., Schwalb, J., Schafer, C., and Hormann, K. 2000. Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta otolaryngologica 120:105-111.
32. Linderholm, B., Lindh, B., Tavelin, B., Grankvist, K., and Henriksson, R. 2000. p53 and vascular-endothelial-growthfactor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 89:51-62.
33. Linderholm, B.K., Lindahl, T., Holmberg, L., Klaar, S., Lennerstrand, J., Henriksson, R., and Bergh, J. 2001. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 61:2256-2260.
34. Narendran, A., Ganjavi, H., Morson, N., Connor, A., Barlow, J.W., Keystone, E., Malkin, D., and Freedman, M.H. 2003. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 31:693-701.
35. Kamat, C.D., Green, D.E., Warnke, L., Thorpe, J.E., Ceriello, A., and Ihnat, M.A. 2007. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer letters 249:209-219.
36. Teodoro, J.G., Evans, S.K., and Green, M.R. 2007. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. Journal of molecular medicine 85:1175-1186.
37. Ince, W.L., Jubb, A.M., Holden, S.N., Holmgren, E.B., Tobin, P., Sridhar, M., Hurwitz, H.I., Kabbinavar, F., Novotny, W.F., Hillan, K.J., et al. 2005. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97:981-989.
38. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., and Holmberg, L. 1995. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029-1034.
39. Eberhard, D.A., Johnson, B.E., Amler, L.C., Goddard, A.D., Heldens, S.L., Herbst, R.S., Ince, W.L., Janne, P.A., Januario, T., Johnson, D.H., et al. 2005. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall- cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909.
40. Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. 2006. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346.
41. Nosho, K., Kawasaki, T., Ohnishi, M., Suemoto, Y., Kirkner, G.J., Zepf, D., Yan, L., Longtine, J.A., Fuchs, C.S., and Ogino, S. 2008. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10:534-541.
42. Zuo, Z., Chen, S.S., Chandra, P.K., Galbincea, J.M., Soape, M., Doan, S., Barkoh, B.A., Koeppen, H., Medeiros, L.J., and Luthra, R. 2009. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 22:1023-1031.
43. Curtin, J.A., Fridlyand, J., Kageshita, T., Patel, H.N., Busam, K.J., Kutzner, H., Cho, K.H., Aiba, S., Brocker, E.B., LeBoit, P.E., et al. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147.
44. Populo, H., Vinagre, J., Lopes, J.M., and Soares, P. 2011. Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. Br J Ophthalmol 95:715-719.
45. Heideman, D.A., Snijders, P.J., Bloemena, E., Meijer, C.J., Offerhaus, G.J., Meuwissen, S.G., Gerritsen, W.R., and Craanen, M.E. 2001. Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J Pathol 194:428-435.
46. Sakr, R.A., Barbashina, V., Morrogh, M., Chandarlapaty, S., Andrade, V.P., Arroyo, C.D., Olvera, N., and King, T.A. 2010. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 18:371-374.